<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742209</url>
  </required_header>
  <id_info>
    <org_study_id>111381</org_study_id>
    <nct_id>NCT00742209</nct_id>
  </id_info>
  <brief_title>Prevention Study in Adult Patients Suffering From Migraine Headaches</brief_title>
  <official_title>Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XenoPort, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>XenoPort, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to evaluate dose response relationship, efficacy, safety and
      tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment
      of migraine headache. Once subjects complete the baseline and meet the randomization
      criteria, they will complete a 5-wk flexible titration period and then enter the 12 week
      maintenance period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MPX111381 is a multicenter, randomized, double-blind, placebo-controlled, parallel group,
      flexible-dose evaluation of GSK1838262 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
      compared with placebo in the prophylactic treatment of migraine headache.

      Subjects 18 years of age must have experienced at least three migraine headache attacks (with
      or without aura according to 2004 International Headache Society [IHS] criteria 1.1 and
      1.2.1) per month during the 3 months prior to screening and at least four migraine headache
      days but less than 15 total headache days (migraine or non-migraine) per month during the 3
      months prior to screening and must maintain this requirement throughout the last 4 weeks of
      the baseline period. Approximately 528 subjects from approximately 53 centers in North
      America will be randomized in a 2:1:2:2:1 ratio to the following treatment groups: placebo,
      GSK1838262 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day. Investigational product
      will be administered twice daily (morning and evening) with food (e.g., meal or snack).

      The study will consist of six study periods for a total study duration of up to 30 weeks:
      Screening (2 weeks), baseline (including randomization, 6 weeks), flexible titration (5
      weeks), maintenance (12 weeks), taper (3 weeks) and post-treatment (2 weeks). The flexible
      titration administration of investigational product is designed to allow subjects to reach
      the target dose for maintenance treatment or, if unable to reach this target dose, to achieve
      a maximum tolerated dose for maintenance treatment. Subjects will have the opportunity to
      undergo a single dose (600 mg/day) downward adjustment during the flexible titration period
      if intolerability at the current dose occurs. Subsequently, if a single dose downward
      adjustment has occurred, no further dose adjustments in the study (upward or downward) will
      be permitted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline was calculated as the mean number of MHD over the last 4 weeks of treatment prior to taper minus the number at baseline using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of MHD in All Study Phases</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in the Number of Migraine Attacks</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>A migraine attack is defined as a migraine headache of at least 30 minutes in duration and may also include recurring non-migraine or migraine headaches . Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine attacks using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Number of Migraine Headache Periods (MHP)</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>A migraine headache period is a 24-hour block of time that begins at the onset of a migraine event . The 24-hour period is not linked directly with a calendar day. The change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache periods using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Migraine Attack Duration</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The total duration of a migraine attack is measured from migraine attack onset until the resolution of the attack measured in hours and may include more than 1 headache event. The duration is assessed using a Daily Migraine Diary. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Peak Migraine Pain Severity</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>Peak Migraine Pain Severity was measured using a 4-point scale (0=none, 1=mild, 2=moderate, or 3=severe) on a participant self assessed Daily Migraine Diary. The scale measured the maximum pain severity across all headache events considered to be one attack.. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Days of Acute Migraine Medication Use</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The Number of Days of Acute Migraine Medication Use was assessed via the participant-assessed Daily Migraine Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The Number of Acute Migraine Medication Doses Administered was captured via the participant-assessed Daily Migraine Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Triptan Use</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The Number of Acute Migraine Medication Administered was measured via the participant-assessed Daily Migraine Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Opioid Use</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The Number of Acute Migraine Medication Doses Administered by Opioid Use was measured via the participant-assessed Daily Migraine Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication Use</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication use was measured via the participant-assessed Daily Migraine Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Percentage of Migraine Attacks With Each of the Following Migraine Symptoms: Aura, Nausea, Vomiting, Photophobia, Phonophobia</measure>
    <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
    <description>The endpoint is defined as the percentage of attacks with each symptom (separately) for each study phase. Migraine symptoms aura, nausea, vomiting, photophobia, and phonophobia are defined as the presence of each migraine symptom during any of the headache events within an attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Classified as Responders for Each of the Following Measures: Migraine Headache Days, Migraine Attacks, and Migraine Headache Periods</measure>
    <time_frame>Baseline to the Last 4 weeks of treatment</time_frame>
    <description>A responder is defined as a participant who achieved at least a 50% reduction from baseline for the indicated measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on the 7-point Likert Patient Global Impression of Change (PGIC) Scale Using LOCF at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>The PGIC is a single question measured on the 7-point Likert Scale (1 = &quot;very much improved&quot;; 2 = &quot;much improved&quot;; 7 = &quot;very much worse&quot;). A responder is defined as being &quot;very much improved&quot; or &quot;much improved.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were &quot;Much Improved&quot; or &quot;Very Much Improved&quot; (Responders) on the 7-point Likert Clinical Global Impression of Change (CGIC) Scale Using LOCF at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>The CGIC is a single question measured on a 7-point Likert Scale. (1 = &quot;very much improved&quot;; 2= &quot;much improved, and 7 = &quot;very much worse&quot;) designed to give an assessment of treatment from a clinician's perspective. A responder is defined as being 'Very much improved' or 'much improved'.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ v2.1) Composite Score and Subscales (Role Function Restrictive, Role Function, Preventive, &amp; Emotional Function) at Week 17</measure>
    <time_frame>Baseline and Week 17</time_frame>
    <description>The MSQ is a 14-item health-related quality of life (HRQOL) questionnaire. Participants provide responses using a 6-point Likert scale (1=None of the time, 2= A little bit of the time, 3=Some of the time, 4=A good bit of the time, 5=Most of the time, 6=All of the time) that are then recoded with a final item value where 1=6, 2=5, 3=4, 4=3, 5=2, and 6=1. The scale measures 3 independently scored dimensions (Role Function Restrictive, Role Function, Preventive, and Emotional Function) of HRQOL that are affected by migraine. For each dimension, a higher score indicates a better health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in the Headache Impact Test (HIT-6) Total Scores at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>The HIT is a 6-item, self-administered HRQOL questionnaire used to measure six areas that impact headaches have on participants' ability to function on the job, at school, at home, and in social situations. Participants provide responses to questions using a 5-point Likert-type scale. All item values range from 6 to13.The total scores range from 36 to 78, where higher scores indicate greater impact on a participant's life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in Productivity as Measured by Lost Time Equivalents (LTE) - (Work Activities, Non-work Activities, and Combination of Work and Non-work Activities)</measure>
    <time_frame>Week 17</time_frame>
    <description>Productivity, as measured by LTE, is a metric used to assess productivity loss in migraine. It is a composite measure of presenteeism (continued to work while under the influence of migraine symptoms) and absenteeism (time missed from work due to migraine), and can be applied to productivity for work and non-work activities. Productivity data were collected via an e-diary, and productivity measures were summarized for each study phase by averaging each measure across migraine attacks for each participant.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Treatment Satisfaction Using the Patient Perception of Migraine Questionnaire (PPMQ-R) at Week 17</measure>
    <time_frame>Week 17</time_frame>
    <description>Three global treatment satisfaction items from the PPMQ included satisfaction or dissatisfaction with Medication Effectiveness, Medication Side Effects, and Overall Medication. Each item on the PPMQ uses a 7-point satisfaction scale (1 = Very Satisfied to 7 = Very Dissatisfied). Satisfied participants include those reporting &quot;Very Satisfied&quot; (scale value = 1) or &quot;Satisfied&quot; (scale value = 2) on the scale.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Migraine Disorders</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK 1838262 1200 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 or 1200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK 1838262 1800 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 or 1200 or 1800 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK 1838262 2400 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 or 1200 or 1800 or 2400 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK 1838262 3000 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 or 1200 or 1800 or 2400 or 3000 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1838262</intervention_name>
    <description>Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day</description>
    <arm_group_label>GSK 1838262 3000 mg/day</arm_group_label>
    <arm_group_label>GSK 1838262 2400 mg/day</arm_group_label>
    <arm_group_label>GSK 1838262 1800 mg/day</arm_group_label>
    <arm_group_label>GSK 1838262 1200 mg/day</arm_group_label>
    <other_name>XP13512</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Outpatient subjects aged 18 years or older.

          -  Females of non-childbearing potential. If of child-bearing potential, is not lactating
             and has a negative pregnancy test 7 days prior to study treatment initiation and
             agrees to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for
             avoiding pregnancy.

          -  Subjects suffering from migraine headache with or without aura, according to 2004 IHS
             criteria 1.1 and 1.2.1.

          -  Subject has had a history of migraine headache for at least one year, and the age of
             onset was prior to 50 years.

          -  Subject has consistent migraine headache over time (i.e., incidence and severity).

          -  Subject has had at least three migraine headache attacks per month during the 3 months
             prior to screening and maintains this requirement during the last 4 weeks of the
             baseline period

          -  Subject has had at least four migraine headache days but less than 15 total headache
             days (migraine or non-migraine) per month during the 3 months prior to screening and
             maintains this requirement during the last 4 weeks of the baseline period.

          -  Subject is able to distinguish migraine headache attacks as discrete from other
             headaches (i.e., tension-type headaches).

          -  Subject has the ability to read, comprehend and legibly and reliably record
             information in paper and electronic format as required by the protocol.

          -  Subject must be able to provide written informed consent prior to participation in the
             study. The contents and process of obtaining informed consent will be in accordance
             with all applicable regulatory requirements.

        Exclusion Criteria:

          -  Subject has a history of ergotamine, triptan, opioid, and/or combination pain
             medication use on &gt;/=10 days per month on a regular basis for &gt;/= 3 months.

          -  Subject has failed more than 2 adequate treatments of migraine prophylaxis -where
             failure is defined as a lack of efficacy with treatment duration of at least 8 weeks.

          -  Subject has history of simple analgesic use on &gt;/=15 days per month for &gt;/=3months.

          -  Subject is unable to discontinue prohibited medications during the 2-week screening
             period and throughout the duration of the study including beta-blockers,
             benzodiazepines, tricyclic antidepressants, calcium channel blockers, antiepileptic
             drugs, bupropion or serotonergic noradrenergic reuptake inhibitors (SNRIs).

          -  Subjects who have taken gabapentin or pregabalin previously for the prophylactic
             treatment of migraine headache. Subjects who have taken gabapentin or pregabalin for
             treatment of conditions other than migraine are eligible provided, (1) their total
             exposure to gabapentin and pregabalin is less than 3 months during the preceding 12
             months, and (2) the subject stopped taking gabapentin or pregabalin for at least 3
             months prior to baseline.

          -  Subject has a history of cluster headaches or basilar, ophthalmoplegic, hemiplegic, or
             transformed migraine headaches.

          -  Subject has a current or past history of seizure disorder.

          -  Subject has any of the following medical conditions, laboratory abnormalities or
             disorders:

          -  Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt;2x upper limit of normal (ULN) or alkaline phosphatase or
             bilirubin &gt;1.5x ULN

          -  Chronic hepatitis B or C with a positive Hepatitis B surface antigen (HBsAg) or
             Hepatitis C Core Antigen Antibody (Hep C antibody)

          -  Impaired renal function defined as either creatinine clearance &lt;60 mL/min (estimation
             of creatinine clearance by Cockroft and Gault Method) or renal dysfunction requiring
             hemodialysis

          -  Corrected QT (QTc) interval &gt;/= 450 msec based on the average QTc value of triplicate
             electrocardiograms (ECGs) obtained by the central ECG reader over a brief recording
             period

          -  QTc interval &gt;/= 480 msec for subjects with Bundle Branch Block based on the average
             QTc value of triplicate ECGs obtained by the central ECG reader over a brief recording
             period

          -  Uncontrolled hypertension at screen or at time of randomization (sitting systolic
             blood pressure [SBP] &gt;160 mmHg and/or sitting diastolic blood pressure [DBP] &gt;90 mmHg)

          -  Medical condition or disorder that would interfere with the action, absorption,
             distribution, metabolism, or excretion of GSK1838262, or, in the investigator's
             judgement:

          -  Is considered to be clinically significant and may pose a safety concern, or,

          -  Could interfere with the accurate assessment of safety or efficacy, or,

          -  Could potentially affect a subject's safety or study outcome.

          -  Subject meets criteria as defined by the Diagnostic and Statistical Manual of Mental
             Disorders (DSM-IV-TR) for a major depressive episode or for active significant
             psychiatric disorders within the past year, including dementia, general anxiety
             disorder, psychotic disorders or bipolar disorder.

          -  Subjects with a history of depression that is in remission, with or without
             antidepressant treatment, may participate, unless a stable antidepressant regimen
             includes a prohibited medication.

          -  Antidepressant medication may not be changed or discontinued to meet entry criteria
             and must be stable for at least 3 months prior to screening.

          -  Subject has a history of clinically significant drug or alcohol abuse as defined by
             DSM IV TR or is unable to refrain from substance abuse throughout the study.

          -  Subject is currently participating in another clinical study in which the subject is,
             or will be exposed to an investigational or non-investigational drug or device.

          -  Subject has participated in a clinical study in which the subject was exposed to an
             investigational or non investigational drug or device:

          -  Within the preceding month for studies unrelated to the current illness (migraine
             headaches), or

          -  Within the preceding 3 months for studies related to the current illness (migraine
             headaches).

          -  Subjects who have taken botulinum toxin type A (Botox) within the past 6 months.

          -  Subject has a history of an allergic reaction, or a medically significant adverse
             reaction to the investigational product or excipients, which, in the opinion of the
             investigator, makes a subject unsuitable for participation in the study.

          -  Subject is felt to be at risk of non-compliance (e.g., for taking investigational
             product or for completing the electronic diary [e-diary]), in the investigator's
             opinion.

          -  Subject is a pregnant or nursing woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V4H 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>October 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2011</results_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 3 subjects who were randomized but did not take investigational product, and, therefore, were not included in the Safety, Intent to Treat (ITT), or Per Protocol (PP) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral GEn (XP13512) placebo</description>
        </group>
        <group group_id="P2">
          <title>GEn 1200 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day.</description>
        </group>
        <group group_id="P3">
          <title>GEn 1800 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
        </group>
        <group group_id="P4">
          <title>GEn 2400 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
        </group>
        <group group_id="P5">
          <title>GEn 3000 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="134"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral GEn (XP13512) placebo on Weeks 1-17</description>
        </group>
        <group group_id="B2">
          <title>GEn 1200 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day.</description>
        </group>
        <group group_id="B3">
          <title>GEn 1800 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day.</description>
        </group>
        <group group_id="B4">
          <title>GEn 2400 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day.</description>
        </group>
        <group group_id="B5">
          <title>GEn 3000 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="134"/>
            <count group_id="B4" value="133"/>
            <count group_id="B5" value="62"/>
            <count group_id="B6" value="523"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="11.72"/>
                    <measurement group_id="B2" value="39.4" spread="9.74"/>
                    <measurement group_id="B3" value="37.7" spread="11.75"/>
                    <measurement group_id="B4" value="39.0" spread="12.04"/>
                    <measurement group_id="B5" value="39.1" spread="11.78"/>
                    <measurement group_id="B6" value="39.2" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage (AA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian (AI) or Alaska Native (AN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AA/African Heritage and AI or AN and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AA/African Heritage and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AI or AN and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper</title>
        <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline was calculated as the mean number of MHD over the last 4 weeks of treatment prior to taper minus the number at baseline using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>Intent to treat (ITT). There were 3 subjects who were randomized but did not take investigational product, and, therefore were not included in the Safety, ITT, or Per Protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>Average of GEn 1800/2400 mg</title>
            <description>Average of GEn 1800 mg group and GEn 2400 mg group</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper</title>
          <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline was calculated as the mean number of MHD over the last 4 weeks of treatment prior to taper minus the number at baseline using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>Intent to treat (ITT). There were 3 subjects who were randomized but did not take investigational product, and, therefore were not included in the Safety, ITT, or Per Protocol (PP) population.</population>
          <units>Migraine Headache Days (MHD)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.38"/>
                    <measurement group_id="O2" value="-3.6" spread="0.26"/>
                    <measurement group_id="O3" value="-3.8" spread="0.37"/>
                    <measurement group_id="O4" value="-3.3" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.579</p_value>
            <p_value_desc>A combination of a sequential method and the Hochberg procedure has been used to maintain the overall experiment-size alphas level of 0.05 for the comparison of GEn vs. placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>An ANCOVA model with baseline number of MHD and IHS Headache Classification for presence or absence of aura as covariates was used.</method_desc>
            <param_type>Adjusted mean difference versus placebo</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Adjusted mean difference versus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of MHD in All Study Phases</title>
        <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of MHD in All Study Phases</title>
          <description>A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>ITT Population</population>
          <units>Migraine Headache Days (MHD)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="124"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Titration(n=124, 59, 119, 124, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.434" spread="0.3621"/>
                    <measurement group_id="O2" value="-1.920" spread="0.5224"/>
                    <measurement group_id="O3" value="-2.431" spread="0.3375"/>
                    <measurement group_id="O4" value="-2.573" spread="0.3352"/>
                    <measurement group_id="O5" value="-2.325" spread="0.5055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 2nd 4-Week (n=124, 59, 119, 124, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.595" spread="0.3784"/>
                    <measurement group_id="O2" value="-2.739" spread="0.6897"/>
                    <measurement group_id="O3" value="-3.953" spread="0.3794"/>
                    <measurement group_id="O4" value="-3.360" spread="0.4201"/>
                    <measurement group_id="O5" value="-3.520" spread="0.5669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 3rd 4-Week (n=124, 59, 119, 124, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.865" spread="0.3992"/>
                    <measurement group_id="O2" value="-3.171" spread="0.6660"/>
                    <measurement group_id="O3" value="-3.9888" spread="0.3810"/>
                    <measurement group_id="O4" value="-3.439" spread="0.4483"/>
                    <measurement group_id="O5" value="-3.220" spread="0.6594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Maint Phase (n=112, 54, 101, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.846" spread="0.3589"/>
                    <measurement group_id="O2" value="-2.854" spread="0.6565"/>
                    <measurement group_id="O3" value="-4.047" spread="0.3368"/>
                    <measurement group_id="O4" value="-3.794" spread="0.3761"/>
                    <measurement group_id="O5" value="-3.723" spread="0.6492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Treat Phase (n=118, 56, 113, 118, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.396" spread="0.3422"/>
                    <measurement group_id="O2" value="-2.834" spread="0.5640"/>
                    <measurement group_id="O3" value="-3.579" spread="0.3140"/>
                    <measurement group_id="O4" value="-3.393" spread="0.3388"/>
                    <measurement group_id="O5" value="-3.193" spread="0.5165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 1st 4-Week (n=124, 59, 119,124, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.147" spread="0.4043"/>
                    <measurement group_id="O2" value="-2.191" spread="0.6758"/>
                    <measurement group_id="O3" value="-3.424" spread="0.3204"/>
                    <measurement group_id="O4" value="-3.419" spread="0.3941"/>
                    <measurement group_id="O5" value="-2.974" spread="0.5522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in the Number of Migraine Attacks</title>
        <description>A migraine attack is defined as a migraine headache of at least 30 minutes in duration and may also include recurring non-migraine or migraine headaches . Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine attacks using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in the Number of Migraine Attacks</title>
          <description>A migraine attack is defined as a migraine headache of at least 30 minutes in duration and may also include recurring non-migraine or migraine headaches . Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine attacks using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>ITT Population</population>
          <units>Migraine Attacks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.15"/>
                    <measurement group_id="O2" value="-2.2" spread="0.22"/>
                    <measurement group_id="O3" value="-2.3" spread="0.16"/>
                    <measurement group_id="O4" value="-2.1" spread="0.15"/>
                    <measurement group_id="O5" value="-2.6" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Number of Migraine Headache Periods (MHP)</title>
        <description>A migraine headache period is a 24-hour block of time that begins at the onset of a migraine event . The 24-hour period is not linked directly with a calendar day. The change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache periods using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Number of Migraine Headache Periods (MHP)</title>
          <description>A migraine headache period is a 24-hour block of time that begins at the onset of a migraine event . The 24-hour period is not linked directly with a calendar day. The change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache periods using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>ITT Population</population>
          <units>Migraine Headache Periods (MHP)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.35"/>
                    <measurement group_id="O2" value="-3.0" spread="0.50"/>
                    <measurement group_id="O3" value="-3.6" spread="0.36"/>
                    <measurement group_id="O4" value="-3.0" spread="0.34"/>
                    <measurement group_id="O5" value="-3.2" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Migraine Attack Duration</title>
        <description>The total duration of a migraine attack is measured from migraine attack onset until the resolution of the attack measured in hours and may include more than 1 headache event. The duration is assessed using a Daily Migraine Diary. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Migraine Attack Duration</title>
          <description>The total duration of a migraine attack is measured from migraine attack onset until the resolution of the attack measured in hours and may include more than 1 headache event. The duration is assessed using a Daily Migraine Diary. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). Change from baseline is calculated as post-baseline minus baseline. The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>ITT Population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="3.355"/>
                    <measurement group_id="O2" value="3.01" spread="5.720"/>
                    <measurement group_id="O3" value="-2.93" spread="3.658"/>
                    <measurement group_id="O4" value="2.59" spread="5.000"/>
                    <measurement group_id="O5" value="9.82" spread="9.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Peak Migraine Pain Severity</title>
        <description>Peak Migraine Pain Severity was measured using a 4-point scale (0=none, 1=mild, 2=moderate, or 3=severe) on a participant self assessed Daily Migraine Diary. The scale measured the maximum pain severity across all headache events considered to be one attack.. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Peak Migraine Pain Severity</title>
          <description>Peak Migraine Pain Severity was measured using a 4-point scale (0=none, 1=mild, 2=moderate, or 3=severe) on a participant self assessed Daily Migraine Diary. The scale measured the maximum pain severity across all headache events considered to be one attack.. Change from baseline and the last 4 weeks of treatment prior to taper were calculated means of the number of migraine headache days using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.</description>
          <population>ITT Population</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.058"/>
                    <measurement group_id="O2" value="-0.13" spread="0.086"/>
                    <measurement group_id="O3" value="-0.12" spread="0.055"/>
                    <measurement group_id="O4" value="-0.04" spread="0.050"/>
                    <measurement group_id="O5" value="-0.09" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Days of Acute Migraine Medication Use</title>
        <description>The Number of Days of Acute Migraine Medication Use was assessed via the participant-assessed Daily Migraine Diary.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Days of Acute Migraine Medication Use</title>
          <description>The Number of Days of Acute Migraine Medication Use was assessed via the participant-assessed Daily Migraine Diary.</description>
          <population>ITT Population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.28"/>
                    <measurement group_id="O2" value="-2.3" spread="0.39"/>
                    <measurement group_id="O3" value="-2.7" spread="0.28"/>
                    <measurement group_id="O4" value="-2.2" spread="0.27"/>
                    <measurement group_id="O5" value="-2.1" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered</title>
        <description>The Number of Acute Migraine Medication Doses Administered was captured via the participant-assessed Daily Migraine Diary.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered</title>
          <description>The Number of Acute Migraine Medication Doses Administered was captured via the participant-assessed Daily Migraine Diary.</description>
          <population>ITT Population</population>
          <units>Acute Medication Doses Admin.</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.69"/>
                    <measurement group_id="O2" value="-4.8" spread="0.97"/>
                    <measurement group_id="O3" value="-5.8" spread="0.70"/>
                    <measurement group_id="O4" value="-5.1" spread="0.67"/>
                    <measurement group_id="O5" value="-4.5" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Triptan Use</title>
        <description>The Number of Acute Migraine Medication Administered was measured via the participant-assessed Daily Migraine Diary.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Triptan Use</title>
          <description>The Number of Acute Migraine Medication Administered was measured via the participant-assessed Daily Migraine Diary.</description>
          <population>ITT Population</population>
          <units>Acute Migraine Medication Dose</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triptan Use (n= 72, 30, 65, 63, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.88"/>
                    <measurement group_id="O2" value="-2.9" spread="1.35"/>
                    <measurement group_id="O3" value="-4.9" spread="0.91"/>
                    <measurement group_id="O4" value="-4.3" spread="0.93"/>
                    <measurement group_id="O5" value="-2.6" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not a Triptan User (n = 48, 29, 49, 60, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="1.06"/>
                    <measurement group_id="O2" value="-6.7" spread="1.36"/>
                    <measurement group_id="O3" value="-6.9" spread="1.05"/>
                    <measurement group_id="O4" value="-6.0" spread="0.95"/>
                    <measurement group_id="O5" value="-6.8" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Opioid Use</title>
        <description>The Number of Acute Migraine Medication Doses Administered by Opioid Use was measured via the participant-assessed Daily Migraine Diary.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Opioid Use</title>
          <description>The Number of Acute Migraine Medication Doses Administered by Opioid Use was measured via the participant-assessed Daily Migraine Diary.</description>
          <population>ITT Population</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Opioid Use (n=20, 7, 14, 26, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.66"/>
                    <measurement group_id="O2" value="1.4" spread="2.81"/>
                    <measurement group_id="O3" value="-3.2" spread="1.97"/>
                    <measurement group_id="O4" value="-6.0" spread="1.45"/>
                    <measurement group_id="O5" value="-5.1" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Opioid Use (n=100, 52, 100, 97, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="0.75"/>
                    <measurement group_id="O2" value="-5.7" spread="0.75"/>
                    <measurement group_id="O3" value="-6.2" spread="0.74"/>
                    <measurement group_id="O4" value="-4.9" spread="0.75"/>
                    <measurement group_id="O5" value="-4.4" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication Use</title>
        <description>The Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication use was measured via the participant-assessed Daily Migraine Diary.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 4-Week Treatment Phase in the Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication Use</title>
          <description>The Number of Acute Migraine Medication Doses Administered by Prescription Headache Medication use was measured via the participant-assessed Daily Migraine Diary.</description>
          <population>ITT Population</population>
          <units>Acute Migraine Medication Doses</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uses Prescription HA meds (n=89, 38, 80, 88, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.78"/>
                    <measurement group_id="O2" value="-3.5" spread="1.19"/>
                    <measurement group_id="O3" value="-4.9" spread="0.82"/>
                    <measurement group_id="O4" value="-4.0" spread="0.78"/>
                    <measurement group_id="O5" value="-3.3" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uses OTC HA meds only (n=31, 21, 34, 35, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="1.31"/>
                    <measurement group_id="O2" value="-7.2" spread="1.59"/>
                    <measurement group_id="O3" value="-7.8" spread="1.25"/>
                    <measurement group_id="O4" value="-7.9" spread="1.23"/>
                    <measurement group_id="O5" value="-6.9" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Percentage of Migraine Attacks With Each of the Following Migraine Symptoms: Aura, Nausea, Vomiting, Photophobia, Phonophobia</title>
        <description>The endpoint is defined as the percentage of attacks with each symptom (separately) for each study phase. Migraine symptoms aura, nausea, vomiting, photophobia, and phonophobia are defined as the presence of each migraine symptom during any of the headache events within an attack.</description>
        <time_frame>Baseline and last 4 weeks of treatment prior to taper (up to Week 17)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Migraine Attacks With Each of the Following Migraine Symptoms: Aura, Nausea, Vomiting, Photophobia, Phonophobia</title>
          <description>The endpoint is defined as the percentage of attacks with each symptom (separately) for each study phase. Migraine symptoms aura, nausea, vomiting, photophobia, and phonophobia are defined as the presence of each migraine symptom during any of the headache events within an attack.</description>
          <population>ITT Population</population>
          <units>Percentage of MA with migraine symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aura (n=99, 52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="3.640"/>
                    <measurement group_id="O2" value="-3.37" spread="4.834"/>
                    <measurement group_id="O3" value="-7.43" spread="3.230"/>
                    <measurement group_id="O4" value="-0.72" spread="3.044"/>
                    <measurement group_id="O5" value="1.21" spread="4.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (n=125, 62, 123, 121, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="2.73"/>
                    <measurement group_id="O2" value="-3.6" spread="3.92"/>
                    <measurement group_id="O3" value="-8.4" spread="3.01"/>
                    <measurement group_id="O4" value="-5.4" spread="2.50"/>
                    <measurement group_id="O5" value="1.4" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (n=99, 52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2.60"/>
                    <measurement group_id="O2" value="-0.9" spread="2.98"/>
                    <measurement group_id="O3" value="-0.4" spread="3.01"/>
                    <measurement group_id="O4" value="3.7" spread="0.4"/>
                    <measurement group_id="O5" value="0.4" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia (n=99, 52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.82"/>
                    <measurement group_id="O2" value="-3.5" spread="4.09"/>
                    <measurement group_id="O3" value="-2.1" spread="2.86"/>
                    <measurement group_id="O4" value="-5.5" spread="2.64"/>
                    <measurement group_id="O5" value="0.1" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phonophobia (n=99, 52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="3.14"/>
                    <measurement group_id="O2" value="1.2" spread="3.05"/>
                    <measurement group_id="O3" value="-0.7" spread="3.42"/>
                    <measurement group_id="O4" value="-7.4" spread="2.88"/>
                    <measurement group_id="O5" value="3.6" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Classified as Responders for Each of the Following Measures: Migraine Headache Days, Migraine Attacks, and Migraine Headache Periods</title>
        <description>A responder is defined as a participant who achieved at least a 50% reduction from baseline for the indicated measures.</description>
        <time_frame>Baseline to the Last 4 weeks of treatment</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Classified as Responders for Each of the Following Measures: Migraine Headache Days, Migraine Attacks, and Migraine Headache Periods</title>
          <description>A responder is defined as a participant who achieved at least a 50% reduction from baseline for the indicated measures.</description>
          <population>ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Migraine headache days (n=65, 26, 68, 67, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine attacks (n=64, 31, 67, 67, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine headache periods (n=65, 27, 70, 69, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Much Improved or Very Much Improved on the 7-point Likert Patient Global Impression of Change (PGIC) Scale Using LOCF at Week 17</title>
        <description>The PGIC is a single question measured on the 7-point Likert Scale (1 = very much improved; 2 = &quot;much improved&quot;; 7 = very much worse). A responder is defined as being &quot;very much improved&quot; or &quot;much improved.&quot;</description>
        <time_frame>Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Much Improved or Very Much Improved on the 7-point Likert Patient Global Impression of Change (PGIC) Scale Using LOCF at Week 17</title>
          <description>The PGIC is a single question measured on the 7-point Likert Scale (1 = very much improved; 2 = &quot;much improved&quot;; 7 = very much worse). A responder is defined as being &quot;very much improved&quot; or &quot;much improved.&quot;</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Much Improved or Very Much Improved (Responders) on the 7-point Likert Clinical Global Impression of Change (CGIC) Scale Using LOCF at Week 17</title>
        <description>The CGIC is a single question measured on a 7-point Likert Scale. (1 = very much improved; 2= &quot;much improved, and 7 = very much worse) designed to give an assessment of treatment from a clinician's perspective. A responder is defined as being 'Very much improved' or 'much improved'.</description>
        <time_frame>Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Much Improved or Very Much Improved (Responders) on the 7-point Likert Clinical Global Impression of Change (CGIC) Scale Using LOCF at Week 17</title>
          <description>The CGIC is a single question measured on a 7-point Likert Scale. (1 = very much improved; 2= &quot;much improved, and 7 = very much worse) designed to give an assessment of treatment from a clinician's perspective. A responder is defined as being 'Very much improved' or 'much improved'.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="120"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ v2.1) Composite Score and Subscales (Role Function Restrictive, Role Function, Preventive, &amp; Emotional Function) at Week 17</title>
        <description>The MSQ is a 14-item health-related quality of life (HRQOL) questionnaire. Participants provide responses using a 6-point Likert scale (1=None of the time, 2= A little bit of the time, 3=Some of the time, 4=A good bit of the time, 5=Most of the time, 6=All of the time) that are then recoded with a final item value where 1=6, 2=5, 3=4, 4=3, 5=2, and 6=1. The scale measures 3 independently scored dimensions (Role Function Restrictive, Role Function, Preventive, and Emotional Function) of HRQOL that are affected by migraine. For each dimension, a higher score indicates a better health status.</description>
        <time_frame>Baseline and Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Migraine Specific Quality of Life Questionnaire (MSQ v2.1) Composite Score and Subscales (Role Function Restrictive, Role Function, Preventive, &amp; Emotional Function) at Week 17</title>
          <description>The MSQ is a 14-item health-related quality of life (HRQOL) questionnaire. Participants provide responses using a 6-point Likert scale (1=None of the time, 2= A little bit of the time, 3=Some of the time, 4=A good bit of the time, 5=Most of the time, 6=All of the time) that are then recoded with a final item value where 1=6, 2=5, 3=4, 4=3, 5=2, and 6=1. The scale measures 3 independently scored dimensions (Role Function Restrictive, Role Function, Preventive, and Emotional Function) of HRQOL that are affected by migraine. For each dimension, a higher score indicates a better health status.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Role Function Restrictive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="2.31"/>
                    <measurement group_id="O2" value="38.7" spread="3.12"/>
                    <measurement group_id="O3" value="37.1" spread="2.38"/>
                    <measurement group_id="O4" value="32.8" spread="2.28"/>
                    <measurement group_id="O5" value="30.9" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Function Preventive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="1.98"/>
                    <measurement group_id="O2" value="28.6" spread="2.67"/>
                    <measurement group_id="O3" value="28.0" spread="2.04"/>
                    <measurement group_id="O4" value="23.9" spread="1.96"/>
                    <measurement group_id="O5" value="22.4" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="2.56"/>
                    <measurement group_id="O2" value="37.0" spread="3.46"/>
                    <measurement group_id="O3" value="34.8" spread="2.64"/>
                    <measurement group_id="O4" value="30.4" spread="2.54"/>
                    <measurement group_id="O5" value="25.7" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline in the Headache Impact Test (HIT-6) Total Scores at Week 17</title>
        <description>The HIT is a 6-item, self-administered HRQOL questionnaire used to measure six areas that impact headaches have on participants' ability to function on the job, at school, at home, and in social situations. Participants provide responses to questions using a 5-point Likert-type scale. All item values range from 6 to13.The total scores range from 36 to 78, where higher scores indicate greater impact on a participant's life.</description>
        <time_frame>Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Headache Impact Test (HIT-6) Total Scores at Week 17</title>
          <description>The HIT is a 6-item, self-administered HRQOL questionnaire used to measure six areas that impact headaches have on participants' ability to function on the job, at school, at home, and in social situations. Participants provide responses to questions using a 5-point Likert-type scale. All item values range from 6 to13.The total scores range from 36 to 78, where higher scores indicate greater impact on a participant's life.</description>
          <population>ITT Population</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="0.95"/>
                    <measurement group_id="O2" value="-12.2" spread="1.28"/>
                    <measurement group_id="O3" value="-11.8" spread="0.98"/>
                    <measurement group_id="O4" value="-9.8" spread="0.94"/>
                    <measurement group_id="O5" value="-10.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline in Productivity as Measured by Lost Time Equivalents (LTE) - (Work Activities, Non-work Activities, and Combination of Work and Non-work Activities)</title>
        <description>Productivity, as measured by LTE, is a metric used to assess productivity loss in migraine. It is a composite measure of presenteeism (continued to work while under the influence of migraine symptoms) and absenteeism (time missed from work due to migraine), and can be applied to productivity for work and non-work activities. Productivity data were collected via an e-diary, and productivity measures were summarized for each study phase by averaging each measure across migraine attacks for each participant.</description>
        <time_frame>Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Productivity as Measured by Lost Time Equivalents (LTE) - (Work Activities, Non-work Activities, and Combination of Work and Non-work Activities)</title>
          <description>Productivity, as measured by LTE, is a metric used to assess productivity loss in migraine. It is a composite measure of presenteeism (continued to work while under the influence of migraine symptoms) and absenteeism (time missed from work due to migraine), and can be applied to productivity for work and non-work activities. Productivity data were collected via an e-diary, and productivity measures were summarized for each study phase by averaging each measure across migraine attacks for each participant.</description>
          <population>ITT Population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lost Work Time (n=52, 23, 41, 35, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.49"/>
                    <measurement group_id="O2" value="-0.3" spread="0.73"/>
                    <measurement group_id="O3" value="-0.9" spread="0.55"/>
                    <measurement group_id="O4" value="-0.1" spread="0.59"/>
                    <measurement group_id="O5" value="0.8" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost Activity Time (n=99,52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.74"/>
                    <measurement group_id="O2" value="-0.1" spread="1.02"/>
                    <measurement group_id="O3" value="-1.2" spread="0.78"/>
                    <measurement group_id="O4" value="-1.0" spread="0.73"/>
                    <measurement group_id="O5" value="1.7" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost Time Equivalents (n=99, 52, 89, 102, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.83"/>
                    <measurement group_id="O2" value="-0.5" spread="1.14"/>
                    <measurement group_id="O3" value="-1.7" spread="0.87"/>
                    <measurement group_id="O4" value="-1.1" spread="0.082"/>
                    <measurement group_id="O5" value="2.1" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Treatment Satisfaction Using the Patient Perception of Migraine Questionnaire (PPMQ-R) at Week 17</title>
        <description>Three global treatment satisfaction items from the PPMQ included satisfaction or dissatisfaction with Medication Effectiveness, Medication Side Effects, and Overall Medication. Each item on the PPMQ uses a 7-point satisfaction scale (1 = Very Satisfied to 7 = Very Dissatisfied). Satisfied participants include those reporting &quot;Very Satisfied&quot; (scale value = 1) or &quot;Satisfied&quot; (scale value = 2) on the scale.</description>
        <time_frame>Week 17</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral GEn (XP13512) placebo</description>
          </group>
          <group group_id="O2">
            <title>GEn 1200 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
          </group>
          <group group_id="O3">
            <title>GEn 1800 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
          </group>
          <group group_id="O4">
            <title>GEn 2400 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
          </group>
          <group group_id="O5">
            <title>GEn 3000 mg</title>
            <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Satisfaction Using the Patient Perception of Migraine Questionnaire (PPMQ-R) at Week 17</title>
          <description>Three global treatment satisfaction items from the PPMQ included satisfaction or dissatisfaction with Medication Effectiveness, Medication Side Effects, and Overall Medication. Each item on the PPMQ uses a 7-point satisfaction scale (1 = Very Satisfied to 7 = Very Dissatisfied). Satisfied participants include those reporting &quot;Very Satisfied&quot; (scale value = 1) or &quot;Satisfied&quot; (scale value = 2) on the scale.</description>
          <population>ITT Population</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="120"/>
                <count group_id="O5" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>How Effective Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side Effects of the Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Satisfaction with Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious adverse events (AEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who took at least one tablet of investigational product. There were no participants who took drug and did not have at least one post-baseline efficacy assessment; thus, the Safety and ITT Populations are the same.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral GEn (XP13512) placebo</description>
        </group>
        <group group_id="E2">
          <title>GEn 1200 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Weeks 2-17: 1200 mg/day</description>
        </group>
        <group group_id="E3">
          <title>GEn 1800 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Weeks 3-17: 1800 mg/day</description>
        </group>
        <group group_id="E4">
          <title>GEn 2400 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4-17: 2400 mg/day</description>
        </group>
        <group group_id="E5">
          <title>GEn 3000 mg</title>
          <description>Oral gabapentin enacarbil (GEn; XP13512/GSK1838262). Week 1: 600 mg/day. Week 2: 1200 mg/day. Week 3: 1800 mg/day. Weeks 4: 2400 mg/day. Weeks 5-17: 3000 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Choleslithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Balance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory track infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>XenoPort Call Center</name_or_title>
      <organization>XenoPort, Inc.</organization>
      <phone>877-936-6778</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

